<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893941</url>
  </required_header>
  <id_info>
    <org_study_id>CM310AD001</org_study_id>
    <nct_id>NCT04893941</nct_id>
  </id_info>
  <brief_title>Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Multiple Dose Escalation, Phase Ib/IIa Study to Evaluate the Safety, Tolerance, PK, PD, Immunogenicity and Preliminary Efficacy of Subcutaneously CM310 in Moderate-severe AD Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation&#xD;
      study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of&#xD;
      subcutaneously CM310 in moderate-severe AD subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 3 periods, a up-to-4-week Screening Period, a 4-week randomized&#xD;
      Treatment Period and a 8-week Safety Follow-up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Actual">January 22, 2021</completion_date>
  <primary_completion_date type="Actual">January 22, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters (e.g., Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Peak concentration (Cmax)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Peak concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Area under the plasma concentration-time curve from 0 to ∞ (AUC0-∞)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to ∞ (AUC0-∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Area under the plasma concentration-time curve from 0 to t (AUC0-t)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Clearance rate (CL/F)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Clearance rate (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: Serum Thymus and activation regulated chemokine (TARC)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Serum Thymus and activation regulated chemokine (TARC), total IgE level and blood eosinophil count (EOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: Blood eosinophil count (EOS)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Blood eosinophil count (EOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: Total IgE level</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total IgE level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Proportion of subjects with anti-drug antibody (ADA)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of Participants with anti-drug antibody (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with IGA 0 or 1</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with Investigator's Global Assessment (IGA, on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with a reduction of IGA from baseline of ≥ 2 points</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with a reduction of IGA from baseline of ≥ 2 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with IGA 0 or 1 and a reduction of IGA from baseline of ≥ 2 points</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with IGA 0 or 1 and a reduction of IGA from baseline of ≥ 2 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with EASI-50</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with The Eczema Area and Severity Index(EASI)-50 (≥50 percent improvement from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with EASI-75</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with EASI-75 (≥75 percent improvement from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy: Proportion of subjects with improvement (reduction) of pruritus NRS from baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of subjects with improvement (reduction) of pruritus Numerical Rating Scale(NRS) from baseline; The range of NRS is from 0 (no itch)-10 (worst imaginable itch)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Moderate-to-severe Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>CM310 75mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg for 3 doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM310 150mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg for 3 doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM310 300mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg for 3 doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM310 600(1st)+300mg(2nd,3rd) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 3 doses, every 2 weeks, SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM310</intervention_name>
    <description>IL-4Rα monoclonal antibody</description>
    <arm_group_label>CM310 150mg arm</arm_group_label>
    <arm_group_label>CM310 300mg arm</arm_group_label>
    <arm_group_label>CM310 600(1st)+300mg(2nd,3rd) arm</arm_group_label>
    <arm_group_label>CM310 75mg arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as AD for at least 12 months before Screening, with below requirements:&#xD;
             1)EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 (0-5 points scale) at&#xD;
             Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline; 4)&#xD;
             Pruritus NRS average score ≥3 at Baseline.&#xD;
&#xD;
          -  Inadequate response to topical medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not enough washing-out period for previous therapy.&#xD;
&#xD;
          -  Concurrent disease/status which may potentially affect the efficacy/safety judgement.&#xD;
&#xD;
          -  Organ dysfunction.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Other.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Second Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

